Zacks Investment Research Upgrades Mirna Therapeutics Inc. (MIRN) to Buy
Mirna Therapeutics Inc. (NASDAQ:MIRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm presently has a $1.25 price objective on the stock. Zacks Investment Research’s price objective suggests a potential upside of 6.84% from the stock’s previous close.
According to Zacks, “Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company’s pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. “
MIRN has been the subject of several other reports. HC Wainwright lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $6.00 to $2.00 in a research note on Friday, September 23rd. Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $10.00 to $4.00 in a research note on Monday, August 15th. Oppenheimer Holdings Inc. lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 21st. Citigroup Inc. cut their price target on Mirna Therapeutics from $4.50 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, September 22nd. Finally, Cantor Fitzgerald lowered Mirna Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $14.00 to $2.00 in a research note on Wednesday, September 21st. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $3.63.
Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.17 on Wednesday. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $11.01. The company’s market cap is $24.38 million. The firm’s 50-day moving average price is $1.51 and its 200 day moving average price is $3.24.
Mirna Therapeutics Company Profile
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.